Neoadjuvant Tislelizumab in Combination With Dasatinib and Quercetin in Resectable HNSCC
Status:
Not yet recruiting
Trial end date:
2027-12-01
Target enrollment:
Participant gender:
Summary
The trial is being conducted to evaluate the efficacy and safety of Tislelizumab in
combination with dasatinib and quercetin in patients with head and neck squamous cell
carcinoma who are about to undergo surgery.
Phase:
Phase 2
Details
Lead Sponsor:
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University